<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>20</Volume>
				<Issue>5</Issue>
				<PubDate PubStatus="epublish">
					<Year>2019</Year>
					<Month>05</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Targeting the BRAF Signaling Pathway in CD133pos Cancer Stem Cells of Anaplastic Thyroid Carcinoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>1353</FirstPage>
			<LastPage>1360</LastPage>
			<ELocationID EIdType="pii">86820</ELocationID>
			
<ELocationID EIdType="doi">10.31557/APJCP.2019.20.5.1353</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Farzaneh </FirstName>
					<LastName>Bozorg-Ghalati</LastName>

						<AffiliationInfo>
						<Affiliation>Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation> Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Mehdi </FirstName>
					<LastName>Hedayati</LastName>
<Affiliation>Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>

</Author>
<Author>
					<FirstName>Mehdi </FirstName>
					<LastName>Dianatpour</LastName>

						<AffiliationInfo>
						<Affiliation>Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Stem Cell Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation>
						</AffiliationInfo>

</Author>
<Author>
					<FirstName>Narimann </FirstName>
					<LastName>Mosaffa</LastName>
<Affiliation>Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>

</Author>
<Author>
					<FirstName>Fereidoun </FirstName>
					<LastName>Azizi</LastName>
<Affiliation>Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2017</Year>
					<Month>09</Month>
					<Day>13</Day>
				</PubDate>
			</History>
		<Abstract>Background: Cancer stem cells (CSCs) with a self-renewal ability in tumor cells population, execute a pivotal&lt;br /&gt;function in tumorigenesis, retrogression, and metastasis of malignant cancers such as anaplastic thyroid carcinoma&lt;br /&gt;(ATC). Materials and Methods: In this study, we isolated CSCs subpopulation with CD133 surface marker from&lt;br /&gt;three ATC cell lines by magnetic cell sorting assay. After confirming the segregation by the flow cytometry method,&lt;br /&gt;BRAF and sodium-iodide symporter (NIS) genes were investigated in them before and after incubation with BRAF&lt;br /&gt;inhibitor. Also, we evaluated the NIS protein expression and localization. Results: Established upon q-RT PCR data,&lt;br /&gt;when compared to human normal thyrocytes, the BRAFV600E gene was over-expressed in CD133pos cells (&gt;1705.99 ±&lt;br /&gt;55.55 fold, Mean ± SEM, n=3, P- value&lt;0.05), whilst the expression of NIS gene was very restricted (&lt; 0.0008 ± 5.43&lt;br /&gt;fold, Mean ± SEM, n=3, P- value&lt;0.05) in them. Also, our results showed that BRAF inhibition affected NIS protein&lt;br /&gt;expression and localization. Conclusions: Current study showed that the differentiate genes/proteins expression can&lt;br /&gt;be induced in the CSCs via focus on signal transduction pathways and targeting their molecules, that are involved in&lt;br /&gt;expression of these genes/proteins. Therefore, attention to targeting CSCs along with routine thyroid cancer therapy,&lt;br /&gt;can help to ATC treatment.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Anaplastic thyroid carcinoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Positive CD133 cancer stem cells</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">BRAF inhibition</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Sodium-iodide symporter</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_86820_058f5512033a587709b144839c181686.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
